

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUA MEDICINE

華領醫藥

(Incorporated in the Cayman Islands with limited liability)

(stock code: 2552)

VOLUNTARY ANNOUNCEMENT
INNOVATIVE FIRST-IN-CLASS GKA, HUATANGNING (华堂宁®)
INCLUDED IN THE 2023 NATIONAL REIMBURSEMENT DRUG LIST

This is a voluntary announcement made by Hua Medicine (the “**Company**”, together with its subsidiaries, the “**Group**”) to provide its shareholders and potential investors with information in relation to the latest business update of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company’s innovative first-in-class glucokinase allosteric activator HuaTangNing (华堂宁®) has been successfully included in China’s National Reimbursement Drug List for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (the “**NRDL**”) for Type-2 diabetes by the National Healthcare Security Administration (NHSA). The agreed reimbursed price is RMB5.39 per tablet, which approved for twice daily administration implies RMB10.78 per day. The new version of the NRDL will take effect from 1 January 2024.

The inclusion will bolster the accessibility of HuaTangNing (华堂宁®), allowing more patients with Type-2 diabetes to easily and affordably access a novel therapeutic that can help to improve blood glucose homeostasis.

Cautionary Statement required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, HuaTangNing (华堂宁®) successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board

Hua Medicine

Dr. Li Chen

Chief Executive Officer and Executive Director

Shanghai, 13 December 2023

As at the date of this announcement, the Board of Directors comprises Dr. Li Chen and Mr. George Chien Cheng Lin as executive Directors; Mr. Robert Taylor Nelsen and Dr. Fangxin Li as non-executive Directors; and Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung as independent non-executive Directors.